Amedeo Smart

Free Medical Literature Service

 

Amedeo

Stroke
  Free Subscription

Articles published in
Lancet Neurol
    September 2023
  1. LABEIT B, Michou E, Hamdy S, Trapl-Grundschober M, et al
    The assessment of dysphagia after stroke: state of the art and future directions.
    Lancet Neurol. 2023;22:858-870.
    >> Share

  2. FENG W
    Diagnosis of post-stroke dysphagia: towards better treatment.
    Lancet Neurol. 2023;22:778-779.
    >> Share

  3. OSPEL JM, Goyal M
    Prehospital triage in acute stroke: which questions to ask?
    Lancet Neurol. 2023;22:771-772.
    >> Share

  4. D'GAMA AM, Mulhern S, Sheidley BR, Boodhoo F, et al
    Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study.
    Lancet Neurol. 2023;22:812-825.
    >> Share

  5. GUTERUD M, Fagerheim Bugge H, Roislien J, Kramer-Johansen J, et al
    Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial.
    Lancet Neurol. 2023;22:800-811.
    >> Share

    August 2023
  6. ODDO M, Taccone FS, Petrosino M, Badenes R, et al
    The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study.
    Lancet Neurol. 2023 Aug 28:S1474-4422(23)00271.
    >> Share

  7. RIZIG M, Bandres-Ciga S, Makarious MB, Ojo OO, et al
    Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
    Lancet Neurol. 2023 Aug 23:S1474-4422(23)00283.
    >> Share

  8. SOLOMON AJ, Arrambide G, Brownlee WJ, Flanagan EP, et al
    Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
    Lancet Neurol. 2023;22:750-768.
    >> Share

  9. MEADOR KJ, Cohen MJ, Loring DW, Matthews AG, et al
    Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study.
    Lancet Neurol. 2023;22:712-722.
    >> Share

  10. MAYNARD G, Kannan R, Liu J, Wang W, et al
    Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
    Lancet Neurol. 2023;22:672-684.
    >> Share

  11. GILADI N, Alcalay RN, Cutter G, Gasser T, et al
    Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2023;22:661-671.
    >> Share

    July 2023
  12. ENGLISH C, Ramage E
    Secondary stroke prevention: more questions than answers.
    Lancet Neurol. 2023 Jul 25:S1474-4422(23)00278.
    >> Share

  13. SCHWARZBACH CJ, Eichner FA, Rucker V, Hofmann AL, et al
    The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00216.
    >> Share

  14. DESBOROUGH MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, et al
    Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Lancet Neurol. 2023;22:557-567.
    >> Share

  15. FRISONI GB, van der Flier W
    STRIVEing to describe small vessel disease.
    Lancet Neurol. 2023;22:548-549.
    >> Share

  16. GRANIT V, Benatar M, Kurtoglu M, Miljkovic MD, et al
    Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
    Lancet Neurol. 2023;22:578-590.
    >> Share

  17. CORBOY JR, Fox RJ, Kister I, Cutter GR, et al
    Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
    Lancet Neurol. 2023;22:568-577.
    >> Share

  18. MEISEL A
    Are CAR T cells the answer to myasthenia gravis therapy?
    Lancet Neurol. 2023;22:545-546.
    >> Share

    June 2023
  19. VAN DER MERWE J
    Stroke care quality-why recognition matters.
    Lancet Neurol. 2023;22:471.
    >> Share

  20. HAYWARD KS, Bernhardt J
    Aspiring to restore arm and hand function after stroke.
    Lancet Neurol. 2023;22:464-465.
    >> Share

    May 2023
  21. DUERING M, Biessels GJ, Brodtmann A, Chen C, et al
    Neuroimaging standards for research into small vessel disease-advances since 2013.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00131.
    >> Share

  22. KOEMANS EA, Chhatwal JP, van Veluw SJ, van Etten ES, et al
    Progression of cerebral amyloid angiopathy: a pathophysiological framework.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00114.
    >> Share

  23. HOWARD JF JR, Bresch S, Genge A, Hewamadduma C, et al
    Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Neurol. 2023;22:395-406.
    >> Share

  24. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
    Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
    Lancet Neurol. 2023;22:383-394.
    >> Share

  25. KASKI D, Koohi N, Haider S, Chandratheva A, et al
    The hyperacute vestibular syndrome: ear or brain?
    Lancet Neurol. 2023;22:377-378.
    >> Share

    April 2023
  26. WU S, Anderson CS
    Antiplatelets for secondary stroke prevention in China.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00130.
    >> Share

  27. PAN Y, Meng X, Yuan B, Johnston SC, et al
    Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00113.
    >> Share

  28. LAVALLEE PC, Charles H, Albers GW, Caplan LR, et al
    Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study.
    Lancet Neurol. 2023;22:320-329.
    >> Share

  29. SAMUELS N, van de Graaf RA, Mulder MJHL, Brown S, et al
    Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis.
    Lancet Neurol. 2023;22:312-319.
    >> Share

  30. BERNHARDT J, Corbett D, Dukelow S, Savitz S, et al
    The International Stroke Recovery and Rehabilitation Alliance.
    Lancet Neurol. 2023;22:295-296.
    >> Share

  31. MAZIGHI M
    The quest for optimal blood pressure management after stroke.
    Lancet Neurol. 2023;22:285-286.
    >> Share

  32. FEIGIN VL, Brainin M, Martins SCO
    The polypill from a public-health perspective.
    Lancet Neurol. 2023;22:294-295.
    >> Share

    March 2023
  33. TSIVGOULIS G, Katsanos AH, Sandset EC, Turc G, et al
    Thrombolysis for acute ischaemic stroke: current status and future perspectives.
    Lancet Neurol. 2023 Mar 9:S1474-4422(22)00519.
    >> Share

  34. REIFF T, Eckstein HH, Mansmann U, Hacke W, et al
    Treatment of asymptomatic carotid stenosis in SPACE-2 - Authors' reply.
    Lancet Neurol. 2023;22:198-199.
    >> Share

  35. SPENCE JD
    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197-198.
    >> Share

  36. GOEL A, Soteriou I, Normando E
    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197.
    >> Share

  37. THORNTON CA, Moxley RT 3rd, Eichinger K, Heatwole C, et al
    Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.
    Lancet Neurol. 2023;22:218-228.
    >> Share

  38. LIPTON RB, Croop R, Stock DA, Madonia J, et al
    Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
    Lancet Neurol. 2023;22:209-217.
    >> Share

    February 2023
  39. ALEMSEGED F, Nguyen TN, Coutts SB, Cordonnier C, et al
    Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice.
    Lancet Neurol. 2023 Feb 10:S1474-4422(22)00483.
    >> Share

  40. MONICHE F, Cabezas-Rodriguez JA, Valverde R, Escudero-Martinez I, et al
    Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial.
    Lancet Neurol. 2023;22:137-146.
    >> Share

  41. SAVITZ SI
    Intra-arterial bone marrow mononuclear cells for stroke.
    Lancet Neurol. 2023;22:105-106.
    >> Share

    January 2023
  42. GOYAL M, Singh N, Ospel J
    Clinical trials in stroke in 2022: new answers and questions.
    Lancet Neurol. 2023;22:9-10.
    >> Share

  43. JENSEN M, Suling A, Metzner A, Schnabel RB, et al
    Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial.
    Lancet Neurol. 2023;22:45-54.
    >> Share

  44. DROUIN E, Pasquini M, Hautecoeur P
    The advent of stroke units.
    Lancet Neurol. 2023;22:31.
    >> Share

  45. CALVERT P, Gupta D, Lip GYH
    Early atrial fibrillation rhythm control after stroke.
    Lancet Neurol. 2023;22:3-4.
    >> Share

  46. PENSATO U, Romoli M, Lazzarin SM, Marcheselli S, et al
    The shortage of thrombolytics for stroke: a call for action.
    Lancet Neurol. 2023;22:28.
    >> Share

    December 2022
  47. ROALDSEN MB, Eltoft A, Wilsgaard T, Christensen H, et al
    Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
    Lancet Neurol. 2022 Dec 19:S1474-4422(22)00484.
    >> Share

  48. MUIR KW
    Treatment of wake-up stroke: stick or TWIST?
    Lancet Neurol. 2022 Dec 19:S1474-4422(22)00515.
    >> Share

  49. THE LANCET NEUROLOGY
    Tackling the burden of stroke with primordial prevention.
    Lancet Neurol. 2022;21:1061.
    >> Share

  50. SOILEAU MJ, Aldred J, Budur K, Fisseha N, et al
    Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
    Lancet Neurol. 2022;21:1099-1109.
    >> Share

    November 2022
  51. KUHLMANN T, Moccia M, Coetzee T, Cohen JA, et al
    Multiple sclerosis progression: time for a new mechanism-driven framework.
    Lancet Neurol. 2022 Nov 18:S1474-4422(22)00289.
    >> Share

  52. CHURILOV L, Bivard A, Parsons MW
    Tenecteplase versus alteplase for early treatment of ischaemic stroke - Authors' reply.
    Lancet Neurol. 2022;21:959.
    >> Share

  53. HUDAIB AR
    Tenecteplase versus alteplase for early treatment of ischaemic stroke.
    Lancet Neurol. 2022;21:959.
    >> Share

    October 2022
  54. HOU C, Lan J, Lin Y, Song H, et al
    Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China.
    Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00335.
    >> Share

  55. GANESH A, Smith EE, Hill MD
    Remote ischaemic conditioning for stroke prevention.
    Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00438.
    >> Share

  56. HOBEANU C, Lavallee PC, Charles H, Labreuche J, et al
    Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study.
    Lancet Neurol. 2022;21:889-898.
    >> Share

  57. REIFF T, Eckstein HH, Mansmann U, Jansen O, et al
    Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial.
    Lancet Neurol. 2022;21:877-888.
    >> Share

  58. BURTON A
    Valeria Caso: because women have strokes too.
    Lancet Neurol. 2022;21:873.
    >> Share

  59. CHRISTENSEN H
    Long-term disability after transient ischaemic attack or minor stroke.
    Lancet Neurol. 2022;21:859-860.
    >> Share

    September 2022
  60. PETER-DEREX L, Philippeau F, Garnier P, Andre-Obadia N, et al
    Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Neurol. 2022;21:781-791.
    >> Share

  61. SYKES L, Akpalu A, Gordon C, Cullen L, et al
    Developing stroke care services in west Africa.
    Lancet Neurol. 2022;21:778-779.
    >> Share

  62. VAN DEN BERG SA, Uniken Venema SM, Reinink H, Hofmeijer J, et al
    Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial.
    Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00333.
    >> Share

  63. SANDSET EC, Walter S, Song L
    The challenges of large-scale prehospital stroke trials.
    Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00356.
    >> Share

    August 2022
  64. BRAININ M, Grisold W, Hankey GJ, Norrving B, et al
    Time to revise primary prevention guidelines for stroke and cardiovascular disease.
    Lancet Neurol. 2022;21:686-687.
    >> Share

    June 2022
  65. BAAK LM, Wagenaar N, van der Aa NE, Groenendaal F, et al
    Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study.
    Lancet Neurol. 2022;21:528-536.
    >> Share

  66. GONZALEZ F, Ferriero DM
    Stem cells for perinatal stroke.
    Lancet Neurol. 2022;21:497-499.
    >> Share

  67. THE LANCET NEUROLOGY
    No area of stroke research should be left behind.
    Lancet Neurol. 2022;21:495.
    >> Share

    May 2022
  68. ROTHWELL PM
    20 years of improvement in stroke care: the rewards from finally funding more research.
    Lancet Neurol. 2022;21:402-404.
    >> Share

    April 2022
  69. BIVARD A, Zhao H, Churilov L, Campbell BCV, et al
    Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00171.
    >> Share

  70. KVISTAD CE, Naess H, Helleberg BH, Idicula T, et al
    Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00124.
    >> Share

  71. COUTTS SB, Yu AYX
    Tenecteplase for acute stroke: the thrombolysis puzzle.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00172.
    >> Share

  72. HILL G, Regan S, Francis R
    Research priorities to improve stroke outcomes.
    Lancet Neurol. 2022;21:312-313.
    >> Share

    March 2022
  73. BONATI LH, Jansen O, de Borst GJ, Brown MM, et al
    Management of atherosclerotic extracranial carotid artery stenosis.
    Lancet Neurol. 2022;21:273-283.
    >> Share

    February 2022
  74. ZHAO J, Yuan F, Song C, Yin R, et al
    Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00010.
    >> Share

  75. DZIEWAS R
    Nutrition in acute stroke management: food for thought.
    Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00078.
    >> Share

  76. GUTIERREZ J, Turan TN, Hoh BL, Chimowitz MI, et al
    Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.
    Lancet Neurol. 2022 Feb 7. pii: S1474-4422(21)00376.
    >> Share

  77. SAMARASEKERA U
    Jeyaraj Pandian: passionate about improving stroke care in India.
    Lancet Neurol. 2022;21:120.
    >> Share

    January 2022
  78. BAILLIEUL S, Dekkers M, Brill AK, Schmidt MH, et al
    Sleep apnoea and ischaemic stroke: current knowledge and future directions.
    Lancet Neurol. 2022;21:78-88.
    >> Share

  79. PUY L, Cordonnier C
    Stroke research in 2021: insights into the reorganisation of stroke care.
    Lancet Neurol. 2022;21:2-3.
    >> Share

    December 2021
  80. FEIGIN VL
    Primary stroke prevention: useful thresholds?
    Lancet Neurol. 2021 Dec 16. pii: S1474-4422(21)00458.
    >> Share

    November 2021
  81. SCHREUDER FHBM, van Nieuwenhuizen KM, Hofmeijer J, Vermeer SE, et al
    Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.
    Lancet Neurol. 2021;20:907-916.
    >> Share

    September 2021
  82. PANDIAN JD, Sebastian IA
    Integrated approach to stroke burden: are we doing enough?
    Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00287.
    >> Share


  83. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00252.
    >> Share

  84. CASO V, Mosconi MG
    Lessons to be learned in intracerebral haemorrhage research.
    Lancet Neurol. 2021 Sep 2. pii: S1474-4422(21)00296.
    >> Share

  85. HOWARD DPJ, Rothwell PM
    Asymptomatic carotid stenosis and stroke risk - Authors' reply.
    Lancet Neurol. 2021;20:699.
    >> Share

  86. ABBOTT A
    Asymptomatic carotid stenosis and stroke risk.
    Lancet Neurol. 2021;20:698-699.
    >> Share

  87. ROTHWELL PM, Buchan AM
    A new thrombolytic drug for acute ischaemic stroke.
    Lancet Neurol. 2021;20:687-689.
    >> Share

  88. GUSEV EI, Martynov MY, Nikonov AA, Shamalov NA, et al
    Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Lancet Neurol. 2021;20:721-728.
    >> Share

    July 2021
  89. BANDINI F, Vestito L, Filippi L
    Prehospital scales in acute ischaemic stroke management.
    Lancet Neurol. 2021;20:504.
    >> Share

  90. DUVEKOT MHC, Venema E, Kerkhoff H, Dippel DWJ, et al
    Prehospital scales in acute ischaemic stroke management - Authors' reply.
    Lancet Neurol. 2021;20:504-505.
    >> Share

    June 2021
  91. LI L, Poon MTC, Samarasekera NE, Perry LA, et al
    Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies.
    Lancet Neurol. 2021;20:437-447.
    >> Share

  92. HAEUSLER KG, Kirchhof P, Kunze C, Tutuncu S, et al
    Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study.
    Lancet Neurol. 2021;20:426-436.
    >> Share

  93. CHENG X, Dong Q
    Towards individualised secondary prevention after intracerebral haemorrhage.
    Lancet Neurol. 2021;20:411-413.
    >> Share

  94. WASSERLAUF J, Volgman AS
    Monitoring for atrial fibrillation after stroke.
    Lancet Neurol. 2021;20:410-411.
    >> Share

    May 2021
  95. SAMARASEKERA U
    Michael Moskowitz: solving the puzzle of migraine.
    Lancet Neurol. 2021 May 17. pii: S1474-4422(21)00141.
    >> Share

  96. JORDAN LC, DeBaun MR, Donahue MJ
    Advances in neuroimaging to improve care in sickle cell disease.
    Lancet Neurol. 2021;20:398-408.
    >> Share

  97. HACHINSKI V, Avan A, Gilliland J, Oveisgharan S, et al
    A new definition of brain health.
    Lancet Neurol. 2021;20:335-336.
    >> Share

    April 2021
  98. WEAVER NA, Kuijf HJ, Aben HP, Abrigo J, et al
    Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts.
    Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00060.
    >> Share

  99. PANTONI L, Salvadori E
    Location of infarcts and post-stroke cognitive impairment.
    Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00107.
    >> Share

  100. BEST JG, Ambler G, Wilson D, Lee KJ, et al
    Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from
    Lancet Neurol. 2021;20:294-303.
    >> Share

  101. GREENBERG SM
    Cerebral microbleeds and prediction of intracranial haemorrhage.
    Lancet Neurol. 2021;20:252-254.
    >> Share

  102. ZIAI WC, Al-Kawaz M
    Blood pressure management after endovascular therapy.
    Lancet Neurol. 2021;20:248-249.
    >> Share

  103. LAUMANN TO, Ortega M, Hoyt CR, Seider NA, et al
    Brain network reorganisation in an adolescent after bilateral perinatal strokes.
    Lancet Neurol. 2021;20:255-256.
    >> Share

    March 2021
  104. SCHMIDT R, Hofer E
    Identifying novel genetic risk loci for lacunar stroke.
    Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00099.
    >> Share

  105. TRAYLOR M, Persyn E, Tomppo L, Klasson S, et al
    Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies.
    Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00031.
    >> Share

  106. ENGELTER ST, Traenka C, Gensicke H, Schaedelin SA, et al
    Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial.
    Lancet Neurol. 2021 Mar 22. pii: S1474-4422(21)00044.
    >> Share

  107. HOWARD DPJ, Gaziano L, Rothwell PM
    Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis.
    Lancet Neurol. 2021;20:193-202.
    >> Share

  108. VAN DIJCK JTJM, Kompanje EJO, Nederkoorn PJ, Peul WC, et al
    Advanced consent for acute stroke trials - Authors' reply.
    Lancet Neurol. 2021;20:170-171.
    >> Share

  109. SHAMY M, Dewar B, Niznick N, Nicholls S, et al
    Advanced consent for acute stroke trials.
    Lancet Neurol. 2021;20:170.
    >> Share

  110. SPENCE JD
    Treatment of asymptomatic carotid stenosis.
    Lancet Neurol. 2021;20:163-165.
    >> Share

    February 2021
  111. MAZIGHI M, Richard S, Lapergue B, Sibon I, et al
    Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
    Lancet Neurol. 2021 Feb 26. pii: S1474-4422(20)30483.
    >> Share

    January 2021
  112. DUVEKOT MHC, Venema E, Rozeman AD, Moudrous W, et al
    Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study.
    Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30439.
    >> Share

  113. GOYAL M, Marko M
    Optimising prehospital stroke triage in a changing landscape.
    Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30488.
    >> Share

  114. TSIVGOULIS G, Katsanos AH
    Important advances in stroke research in 2020.
    Lancet Neurol. 2021;20:2-3.
    >> Share

    December 2020
  115. WU S, Anderson CS
    Healthy eating for secondary stroke prevention.
    Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30450.
    >> Share

  116. ENGLISH C, MacDonald-Wicks L, Patterson A, Attia J, et al
    The role of diet in secondary stroke prevention.
    Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30433.
    >> Share

  117. SILBERGLEIT R, Dickert NW
    Context and principles must drive alternatives to consent in emergency research.
    Lancet Neurol. 2020;19:968-969.
    >> Share

    November 2020
  118. THE LANCET NEUROLOGY
    A unified European action plan on stroke.
    Lancet Neurol. 2020 Nov 6. pii: S1474-4422(20)30409.
    >> Share

    October 2020
  119. MERETOJA A, Yassi N, Wu TY, Churilov L, et al
    Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2020 Oct 28. pii: S1474-4422(20)30369.
    >> Share

  120. KOMPANJE EJO, van Dijck JTJM, Chalos V, van den Berg SA, et al
    Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke.
    Lancet Neurol. 2020 Oct 21. pii: S1474-4422(20)30276.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016